An Open-Label Trial of Aripiprazole in Autism Spectrum Disorders
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the efficacy, safety and tolerability of aripiprazole
monotherapy in the treatment of children and adolescents suffering from Autism Spectrum
Disorder (ASD) over a 12-week period. We hypothesize that aripiprazole may be helpful in
reducing ASD-associated symptoms of anxiety and aggression, resulting in significant
improvements in global outcome.